Drug intelligence / Profile preview

HemPhar

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

HemPhar is a full-spectrum medical cannabis product, specifically formulated with a cannabidiol (CBD) to delta-9-tetrahydrocannabinol (THC) ratio of 10:1. It is being investigated for the treatment of spasticity in patients with severe forms of cerebral palsy. The product is administered as an oral oily solution.

Other names: HemPhar

Targets

GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))FAAHTRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on HemPhar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HemPhar.

Explore the full profile